Physician profile
Raphaelle Woods
NPI 1508228446
$5,312.44
in general payments reported to CMS, 2019-2025
18 companies · $711 in 2025
The $711 reported for 2025 was more than what 80% of Gerontology (Nurse Practitioner) providers received nationally (typical 2025 total: $180).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $15.64 · 2023: $2,343 · 2024: $2,242 · 2025: $711.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,173 · Education: $124.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,172.96 |
| Education | $123.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,813.71 | 2023-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $838.53 | 2023-2024 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $582.59 | 2023-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Axsome Therapeutics, INC. | $392.63 | 2023-2024 | Auvelity |
| Alkermes, INC. | $387.06 | 2023-2024 | Aristada, Lybalvi, Aristada Initio |
| Abbvie INC. | $351.82 | 2023-2024 | |
| Neurocrine Biosciences, INC. | $221.89 | 2023-2024 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $124.15 | 2023-2024 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Indivior INC. | $119.28 | 2023-2024 | Perseris |
| E.R. Squibb & Sons, L.L.C. | $111.60 | 2025 | Cobenfy |
| Lundbeck LLC | $96.90 | 2023-2024 | Rexulti |
| Noven Therapeutics, LLC | $62.85 | 2023 | Xelstrym |
| Takeda Pharmaceuticals U.S.A., INC. | $59.51 | 2023-2024 | Trintellix |
| Corium, LLC | $53.14 | 2023 | Azstarys |
| Abiomed | $39.12 | 2024 | Impella |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $26.15 | 2024 | Qelbree |
| Neuronetics, INC. | $15.87 | 2023 | Neurostar Tms Therapy System |
| Acadia Pharmaceuticals INC | $15.64 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raphaelle Woods listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.